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cardiovascular mortality remains one of the leading causes of death across the globe, accounting to a total of 27.15% of deaths in the Maltese Islands for the year 2014.1  Plaque 
fissuring and/or plaque erosion constitute the foundations of the 
pathogenesis of acute coronary syndromes (ACS) ranging from a 
spectrum of unstable angina, ST elevation myocardial infarction 
(STEMI) and non-STEMI.2   
2015 has been an exceptional year with respect to the progress 
made in the understanding of ACS. Both the European Society 
of Cardiology (ESC)3 and the American  College of Cardiology/
American Heart Association4 published new guidelines on the 
management of ACS in patients without persistent ST-segment 
elevation. This article aims to highlight some of the major 
developments and recommendations that have been put forward.  
One of the major recommendations by ESC and the American 
College of Cardiology/American Heart Association is that, 
following chest pain onset, ACS can be ruled in or ruled out at 0 
and 1 hours if a high sensitivity cardiac troponin test is available. 
Additional testing at 3-6 hours is required if the first 2 troponin 
measurements are not conclusive and the clinical scenario is still 
suggestive of ACS. This was also proposed by Reichlin et al5 who 
concluded that high sensitivity cardiac troponin T baseline values 
and absolute changes within the first hour substantially accelerate 
the management of suspected myocardial infarction (MI) with safe 
rule-out and accurate rule-in of acute MIs. Another significant 
finding concerns triglycerides. ESC and the American College 
of Cardiology/American Heart Association concluded that the 
relationship of triglycerides to the risk of ACS was independent 
of LDL-cholesterol.  Furthermore, fasting triglycerides predicted 
long and short term cardiovascular risk. This highlights the role of 
triglycerides in atherosclerosis, hence pointing out the importance 
of targeting these in both the prevention and management of 
ACS.6
The role of cardiac magnetic resonance in relation to risk 
stratification of patients diagnosed with ACS was also studied. 
Eitel et al7 stated that this is most important if done within 10 
days from the index event in patients with persistent STEMI. 
Furthermore, microvascular obstruction was the only significant 
predictor in addition to TIMI risk score to provide prognostic 
value above clinical risk assessment and left ventricular ejection 
fraction; hence indicating that microvascular obstruction after 
successful epicardial recanalization by primary percutaneous 
coronary intervention (PCI) remains an unmet therapeutic target.7 
The role of thrombectomy in the management of ACS was 
another controversial topic discussed in the guidelines. The 
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Thrombus Aspiration During Percutaneous Coronary Intervention 
in Acute Myocardial Infarction (TAPAS) study8 suggested that the 
removal of thrombi by manual thrombectomy before coronary 
stenting has the potential of reducing distal embolization and 
improving microvascular perfusion hence reducing mortality, whilst 
improving target vessel revascularisation and MI rates. However, 
other studies conducted showed that although improvement in 
ST-segment resolution and distal embolization with thrombectomy 
were achieved, these did not translate in clinical benefits. In 
actual fact, these latter studies reported that thrombectomy failed 
to reduce the development of heart failure or the mortality rate; 
actually, thrombectomy increased significantly the risk of stroke.9,10  
An interesting recommendation was the adoption of a radial 
approach for coronary angiography and PCI rather than femoral 
access. It was proven that the use of radial access reduced major 
bleeding and all-cause mortality whilst not increasing the risk of 
MI or stroke.11 What is more interesting is that in STEMI patients, 
repeated cycles of brief inflations of the angioplasty balloon 
were shown to reduce infarct size and improve the recovery of 
myocardial contractile function.12 Another thought-provoking issue 
is the use of supplemental oxygen in acute MI patients. A study 
showed that there were no benefits with routine oxygen therapy in 
uncomplicated normoxic acute MI patients; in actual fact it was 
found that it increased myocardial injury, increased infarction size 
on cardiac magnetic resonance, with more recurrent MI and more 
frequent arrhythmias.13 Last but not least, the role of aldosterone 
in acute MI was also looked into. In fact, there is a surge in 
aldosterone levels shortly after the onset of MI which has a number 
of deleterious effects such as sodium retention possibly promoting 
arrythmogenesis (in combination with potassium and magnesium 
depletion), endothelial dysfunction, increased vascular tone and 
cardiac remodelling amongst others. In the REMINDER study,14 
patients with acute STEMI without a history of heart failure who 
received epleranone (aldosterone antagonist) within 24 hours of 
symptom onset fared much better than patients with placebo with 
regards to mortality, heart failure, sustained ventricular tachycardia 
or fibrillation, ejection fraction ≤40% and elevated pro-BNP.  
Given the great complexity and vital importance of the 
cardiovascular system, this area is undoubtedly one of the most 
researched and studied to date. New developments and milestones 
are reached daily, altering our clinical practices with the sole aim 
of improving morbidity and mortality. Prevention is better than 
cure and it is with this foresight that the medical profession should 
ascertain that preventive strategies are promoted in an attempt to 
prevent a number of cardiovascular pathologies. re
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